These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 19362948)

  • 1. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
    Horn L; Sandler AB
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1(Suppl 1):S7-16. PubMed ID: 19362948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
    Cabebe E; Wakelee H
    Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy in advanced non-small-cell lung cancer.
    Gettinger S
    Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Hong S; Tan M; Wang S; Luo S; Chen Y; Zhang L
    J Cancer Res Clin Oncol; 2015 May; 141(5):909-21. PubMed ID: 25373315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis Inhibitors in NSCLC.
    Manzo A; Montanino A; Carillio G; Costanzo R; Sandomenico C; Normanno N; Piccirillo MC; Daniele G; Perrone F; Rocco G; Morabito A
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28934120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting angiogenesis in esophagogastric adenocarcinoma.
    Okines AF; Reynolds AR; Cunningham D
    Oncologist; 2011; 16(6):844-58. PubMed ID: 21632459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tumor vasculature as a therapeutic target in non-small cell lung cancer].
    Döme B; Magyar M
    Magy Onkol; 2008 Sep; 52(3):247-59. PubMed ID: 18845495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
    English BC; Price DK; Figg WD
    Cancer Biol Ther; 2009 Jul; 8(13):1214-25. PubMed ID: 19483467
    [No Abstract]   [Full Text] [Related]  

  • 9. [Lung cancer].
    Fischer B; Buhl R
    Med Klin (Munich); 2008 May; 103(5):311-20. PubMed ID: 18484217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis in the treatment of non-small cell lung cancer.
    Horn L; Sandler AB
    Proc Am Thorac Soc; 2009 Apr; 6(2):206-17. PubMed ID: 19349490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
    Manegold C
    Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
    Herbst RS
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S23-30. PubMed ID: 17239287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies in the treatment of advanced/metastatic NSCLC.
    Pallis AG; Serfass L; Dziadziusko R; van Meerbeeck JP; Fennell D; Lacombe D; Welch J; Gridelli C
    Eur J Cancer; 2009 Sep; 45(14):2473-87. PubMed ID: 19596191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
    Lee CB; Socinski MA
    Rev Recent Clin Trials; 2007 May; 2(2):117-20. PubMed ID: 18473996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
    Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
    Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic therapy for breast cancer.
    Nielsen DL; Andersson M; Andersen JL; Kamby C
    Breast Cancer Res; 2010; 12(5):209. PubMed ID: 21067536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of antiangiogenesis therapy: bevacizumab and beyond.
    Cortés-Funes H
    Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug insight: VEGF as a therapeutic target for breast cancer.
    Schneider BP; Sledge GW
    Nat Clin Pract Oncol; 2007 Mar; 4(3):181-9. PubMed ID: 17327858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab in non-small cell lung cancer.
    Di Costanzo F; Mazzoni F; Micol Mela M; Antonuzzo L; Checcacci D; Saggese M; Di Costanzo F
    Drugs; 2008; 68(6):737-46. PubMed ID: 18416583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular therapy for the treatment of hepatocellular carcinoma.
    Greten TF; Korangy F; Manns MP; Malek NP
    Br J Cancer; 2009 Jan; 100(1):19-23. PubMed ID: 19018262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.